Table 1.
Baseline characteristics of groups NLTX and Placebo.
| Characteristics | Total | NLTX | Placebo | P value |
|---|---|---|---|---|
| n = 27 | n = 27 | |||
| Age | ||||
| Mean ± SD | — | 26 ± 11 | 31 ± 12 | 0.03‡ |
| Sex | ||||
| Male | 24 (44.4%) | 9 (33.3%) | 15 (55.6%) | 0.10* |
| Female | 30 (55.6%) | 18 (66.7%) | 12 (44.4%) | |
| Mode of toxicity | ||||
| Suicidal | 45 (83.3%) | 24 (88.9%) | 21 (77.8%) | 0.48** |
| Accidental | 9 (16.7%) | 3 (11.1%) | 6 (22.2%) | |
| Formulation | ||||
| Tablet | 20 (37.0%) | 10 (37.0%) | 10 (37.0%) | >0.99* |
| Syrup | 34 (63.0%) | 17 (63.0%) | 17 (63.0%) | |
| Ingested MTD doses (mg) | ||||
| Mean ± SD | 130 ± 116 | 153 ± 142 | 106 ± 75 | 0.41‡ |
| Time since ingestion (hrs) | ||||
| Mean ± SD | 6 ± 6 | 6 ± 5 | 6 ± 6 | 0.34‡ |
†Student's t-test. ‡Mann-Whitney U test. *Chi-Square test. **Fisher's exact test.